Drug Safety

, Volume 25, Issue 4, pp 251–261 | Cite as

A Systematic Review of the Safety of Kava Extract in the Treatment of Anxiety

Review Article

Abstract

This paper systematically reviews the clinical evidence relating to the safety of extracts of the herbal anxiolytic kava (Piper methysticum). Literature searches were conducted in four electronic databases and the reference lists of all papers located were checked for further relevant publications. Information was also sought from the spontaneous reporting schemes of the WHO and national drug safety bodies and ten manufacturers of kava preparations were contacted.

Data from short-term post-marketing surveillance studies and clinical trials suggest that adverse events are, in general, rare, mild and reversible. However, published case reports indicate that serious adverse events are possible including dermatological reactions, neurological complications and, of greatest concern, liver damage. Spontaneous reporting schemes also suggest that the most common adverse events are mild, but that serious ones occur. Controlled trials suggest that kava extracts do not impair cognitive performance and vigilance or potentiate the effects of central nervous system depressants. However, a possible interaction with benzodiazepines has been reported.

It is concluded that when taken as a short-term monotherapy at recommended doses, kava extracts appear to be well tolerated by most users. Serious adverse events have been reported and further research is required to determine the nature and frequency of such events.

References

  1. 1.
    Pittler MH, Ernst E. Efficacy of kava extract for treating anxiety: systematic review and meta-analysis. J Clin Psychopharmacol 2000; 20: 84–9PubMedCrossRefGoogle Scholar
  2. 2.
    Mathews JD, Riley MD, Fejo L, et al. Effects of the heavy usage of kava on physical health: summary of a pilot survey in an Aboriginal community. Med J Aust 1988; 148: 548–55PubMedGoogle Scholar
  3. 3.
    Norton SA, Ruze P. Kava dermopathy. J Am Acad Dermatol 1994; 31: 89–97PubMedCrossRefGoogle Scholar
  4. 4.
    Spillane PK, Fisher DA, Currie BJ. Neurological manifestations of kava intoxication. Med J Aust 1997; 167: 172–3PubMedGoogle Scholar
  5. 5.
    Chanwai LG. Kava toxicity. Emerg Med 2000; 12: 142–5CrossRefGoogle Scholar
  6. 6.
    Mathews JD, Riley MD. The effects of heavy usage of kava on physical health [letter]. Med J Aust 1988; 149: 342Google Scholar
  7. 7.
    Yates KM, Horsley CAE. ‘Herbal ecstasy’: a case series of adverse reactions. N Z Med J 2000; 113: 315–7PubMedGoogle Scholar
  8. 8.
    Prescott J, Jamieson D, Emdur N, et al. Acute effects of kava on measures of cognitive performance, physiological function and mood. Drug Alcohol Rev 1993; 12: 49–58PubMedCrossRefGoogle Scholar
  9. 9.
    Russell PN, Bakker D, Singh NN. The effects of kava on alerting and speed of access of information from long-term memory. Bull Psychonomic Soc 1987; 25: 236–7Google Scholar
  10. 10.
    Foo H, Lemon J. Acute effects of kava, alone or in combination with alcohol, on subjective measures of impairment and intoxication and on cognitive performance. Drug Alcohol Rev 1997; 16: 147–55PubMedCrossRefGoogle Scholar
  11. 11.
    Unger L. Veränderung psychovegetativer Beschwerden unter Therapie mit Kavain [in German]. Therapiewoche 1988; 38: 3171–4Google Scholar
  12. 12.
    Volz HP, Hänsel R. Kava-Kava und Kavain in der Psychopharmakotherapie [German]. Psychopharmakotherapie 1994; 1: 33–9Google Scholar
  13. 13.
    Saletu B, Grünberger J, Linzmayer L, et al. EEG-brain mapping, psychometric and psychophysiological studies on central effects of kavain - a kava plant derivative. Hum Psychopharmacol 1989; 4: 169–90CrossRefGoogle Scholar
  14. 14.
    Kretschmer W. Kavain als Psychopharmakon [in German]. Munch Med Woschenschr 1970; 112: 154–8Google Scholar
  15. 15.
    Kretschmer W. Psychische Wirkungen von Kavain [in German]. Munch Med Woschenschr 1974; 116: 741–2Google Scholar
  16. 16.
    Krueger H, Kell G. Die Wirkung von Neuronika® auf die motorische Reaktionszeit und die visuell-mentale Verarbeitungszeit [in German]. Therapiewoche 1977; 27: 9417–20Google Scholar
  17. 17.
    Ambrozi L, von Dier Einfluss DL. Kavain (Neuronika®) auf Konzentrationsfähigkeit, Kurzzeitgedächtnis, Reaktionssicherheit und Reaktionsgeschwindigkeit [in German]. Therapiewoche 1979 29: 5967–70Google Scholar
  18. 18.
    Siegers CP, Honold E, Krall B, et al. Ergebnisse einer Anwendungsbeobachtung L1090 mit Laitan® Kapseln [in German]. Arzneimittelforschung 1992; 39: 7–11Google Scholar
  19. 19.
    Hofmann R, Winter U. Therapeutische Möglichkeitenmit Kava Kava bei Angsterkrankungen [in German]. Psycho Zeitschift Praxis Klin 1996; 22: 51–3Google Scholar
  20. 20.
    Bhate H, Gerster G, Gracza E. Orale Prämedikation mit Zubereitungen aus Pipermethysticumbei operativen Eingriffen in Epiduralanästhesie [in German]. Erfahrungsheilkunde 1989; 6: 339–45Google Scholar
  21. 21.
    Warnecke G, Pfaender H, Gerster G, et al. Wirksamkeit von Kawa-kawa-Extrakt beim klimakterischen Syndrom [in German]. Z Phytother 1990; 11: 1–6Google Scholar
  22. 22.
    Warnecke G. Psychsomatische Dysfunktionen im weiblichen Klimakterium [in German]. Fortschr Med 1991; 109: 118–22Google Scholar
  23. 23.
    Kinzler E, Krömer J, Lehmann E. Wirksamkeit eines Kava-Spezial-Extraktes bei Patienten mit Angst-, Spannungs- und Erregungszuständen nicht-psychotischer Genese [in German]. Arzneimittelforschung 1991; 41: 584–8PubMedGoogle Scholar
  24. 24.
    Volz HP, Kieser M. Kava-kava extractWS 1490 versus placebo in anxiety disorders: a randomized placebo-controlled 25-week outpatient trial. Pharmacopsychiatry 1997; 30: 1–5PubMedCrossRefGoogle Scholar
  25. 25.
    Singh NN, Ellis CR, Singh YN. A double-blind, placebo-controlled study of the effects of kava (Kavatrol) on daily stress and anxiety in adults. Altern Ther 1998; 4: 97–8Google Scholar
  26. 26.
    Lehmann E. Wirkung von Kava-Kava bei akuter Angst [in German]. Synopsis Zeitschift Biopsychosoziale Med 1998; 2: 59–64Google Scholar
  27. 27.
    De Leo V, La Marca A, Lanzetta D, et al. Valutazione dell’ associazione di estratto di kava-kava e terapia ormonale sostitutiva nel trattamento d’ansia in postmenopausa [in Italian]. Minerva Ginecol 2000; 52: 263–7PubMedGoogle Scholar
  28. 28.
    Woelk H, Kapoula O, Lehrl S, et al. Behandlung von Angst-Patienten [in German]. Z Allgemeinmed 1993; 69: 271–7Google Scholar
  29. 29.
    Jappe U, Franke I, Reinhold D, et al. Sebotropic drug reaction resulting from kava-kava extract therapy: a new entity? J Am Acad Dermatol 1998; 38: 104–6PubMedCrossRefGoogle Scholar
  30. 30.
    Guro-Razuman S, Anand P, Hu Q, et al. Dermatomyositis-like illness following kava-kava ingestion. J Clin Rheumatol 1999; 5: 342–5PubMedCrossRefGoogle Scholar
  31. 31.
    Schmidt P, Boehncke WH. Delayed-type hypersensitivity reaction to kava-kava extract. Contact Dermatitis 2000; 42: 363–4PubMedGoogle Scholar
  32. 32.
    Süss R, Lehmann P. Hämatogenes Kontaktekzem durch pflanzliche Medikamente am Beispiel des Kavawurzel-extraktes [in German]. Hautarzt 1996; 47: 459–61PubMedCrossRefGoogle Scholar
  33. 33.
    Schelosky L, Raffauf C, Jendroska K, et al. Kava and dopamine antagonism. J Neurol Neurosurg Psychiatry 1995; 58: 639–40PubMedCrossRefGoogle Scholar
  34. 34.
    Stoller R. Leberschädigungen unter Kava-Extrakten [in German]. Schweizerische Ärztezeitung 2000; 31: 1335–6Google Scholar
  35. 35.
    Strahl S. Ehret V, Dahm HH, et al. Nekrotisierende Hepatitis nach Einnahme pflanzlicherHeilmittel [in Dutch]. Dtsch Med Wochenschr 1998; 123: 1410–4PubMedCrossRefGoogle Scholar
  36. 36.
    Escher M, Desmeules J. Hepatitis associated with Kava, a herbal remedy for anxiety. BMJ 2001; 322: 139PubMedCrossRefGoogle Scholar
  37. 37.
    Russmann S, Lauterburg BH, Helbling A. Kava hepatotoxicity. Ann Intern Med 2001; 135: 68–9PubMedGoogle Scholar
  38. 38.
    Donadio V, Bonsi P, Zele I, et al. Myoglobinuria after ingestion of extracts of guarana, Ginkgo biloba and kava [letter]. Neurol Sci 2000; 21: 124PubMedCrossRefGoogle Scholar
  39. 39.
    Almeida JC, Grimsley EW. Coma from the health food store: interaction between kava and alprazolam. Ann Intern Med 1996; 125: 940–1PubMedGoogle Scholar
  40. 40.
    Münte TF, Heinze HJ, Matzke M, et al. Effects of oxazepam and an extract of kava roots (Piper methysticum) on event-related potentials in a word recognition task. Neuropsychobiology 1993; 27: 46–53PubMedCrossRefGoogle Scholar
  41. 41.
    Heinze HJ, Münte TF, Steitz J, et al. Pharmacopsychological effects of oxazepam and kava-extract in a visual search paradigm assessed with event-related potentials. Pharmacopsychiatry 1994; 27: 224–30PubMedCrossRefGoogle Scholar
  42. 42.
    Johnson D, Frauendorf A, Stecker K, et al. Neurophysiologisches Wirkprofil und Verträglichkeit von Kava-Extrakt WS 1490: eine Pilotstudie mit randomisierter Auswertung [in German]. TW Neurol Psychiatr 1991; 5: 349–54Google Scholar
  43. 43.
    Gessner B, Cnota P. Untersuchung der Vigilanz nach Applikation von Kava-Kava-Extrakt, Diazepam oder Plazebo [in German]. Z Phytother 1994; 15: 30–7Google Scholar
  44. 44.
    Herberg KW. Fahrtüchtigkeit nach Einnahme von Kava-Spezial-Extrakt WS 1490, Doppelblinde, placebokontrollierte Studie [in German]. Z Allgemeinmed 1991; 13: 842–6Google Scholar
  45. 45.
    Herberg KW. Influence of kava special extract WS 1490 in combination with ethyl alcohol on safety-related performance parameters. Blutalkohol 1993; 30: 96–105PubMedGoogle Scholar
  46. 46.
    Herberg KW. Safety-related performance after intake of kava-extract, bromazepam and their combination. Z Allgemeinmed 1996; 72: 973–7Google Scholar
  47. 47.
    Emser W, Bartylla K. Verbesserung der Schlafqualität. Zur Wirkung von Kava-Extrakt WS 1490 auf das Schlafmuster bei Gesunden [in German]. TW Neurol Psychiatr 1991; 5: 636–42Google Scholar
  48. 48.
    Barnes J, Mills SY, Abbot NC, et al. Different standards for reporting ADRs to herbal remedies and conventional OTC medicines: face to face interviews with 515 users of herbal remedies. Br J Clin Pharmacol 1998; 45: 496–500PubMedCrossRefGoogle Scholar
  49. 49.
    Ernst E, Barnes J. Methodological approaches to investigating the safety of complementary medicine. Complement Ther Med 1998; 6: 115–21CrossRefGoogle Scholar
  50. 50.
    Blumenthal M, Busse WR, Goldberg A, et al. The complete German Commission E monographs. Austin (TX): American Botanical Council, 1998Google Scholar
  51. 51.
    Baum S, Hill R, Rommelspacher H. Effect of kava extract and individual kavapyrones on neurotransmitter levels in the nucleua accumbens of rats. Prog Neuropsychopharmacol Biol Psychiatry 1998; 22: 1105–20PubMedCrossRefGoogle Scholar
  52. 52.
    Russo E. Handbook of psychotropic herbs: a scientific analysis of herbal remedies for psychiatric conditions. New York: Haworth, 2001: 176–7Google Scholar
  53. 53.
    Barbone F, McMahon AD, Davey PG, et al. Association of road-traffic accidents with benzodiazepine use. Lancet 1998; 352: 1331–6PubMedCrossRefGoogle Scholar
  54. 54.
    Webb G. Kava improperly implicated in semi-comatose patient using conventional drugs. American Botanical Council Herb Clip, 1997 Sep 11Google Scholar

Copyright information

© Adis International Limited 2002

Authors and Affiliations

  1. 1.Department of Complementary MedicineUniversity of ExeterExeterUnited Kingdom

Personalised recommendations